Several Research and Development Activities for providing better treatment of Dermatomyositis Disease are Expected to Propel the Growth of The Global Dermatomyositis Drugs Market

The global dermatomyositis drugs market is anticipated to grow at a considerable CAGR during the forecast years. Dermatomyositis is a rare inflammatory disease that causes weakness in muscles and rashes on the skin. The major factors for the growth of the global dermatomyositis drugs market are the increasing demand for dermatomyositis drugs due to the increasing number of dermatomyositis disease patients and several research and development activities for the better treatment of dermatomyositis disease. For instance, in June 2021, Corbus Pharmaceuticals Holdings, Inc. announced the results from their phase 3 study of Lenabasum as a treatment for dermatomyositis. The study found that lenabasum has a beneficial effect in the treatment of dermatomyositis. 

Browse the full report description of “Global Dermatomyositis Drugs Market Size, Share & Trend Analysis Report by Type (Abatacept, Baricitinib, Dalazatide, Immune Globulin, and IMO-8400), by End-users (Hospitals, Clinics, and Others), Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/dermatomyositis-drug-market

Furthermore, as per the report published in the Indian Journal of Rheumatology in 2020, juvenile dermatomyositis is chronic inflammatory myopathy similar to dermatomyositis has a wide spectrum of disorders that needed a collaborative international clinical trial to study the evidence-based treatment for dermatomyositis. In addition, there are many other studies done and going on for finding the better treatment of dermatomyositis. According to a study published by SAGE journals in 2020, the initial treatment for dermatomyositis is glucocorticosteroids and immunosuppressants. These drugs offer several benefits including stabilization of the disease, decrease in inflammation, and increase in muscle strength. The several research and development activities coupled with the increasing number of patients suffering from dermatomyositis disease are expected to propel the growth of the global dermatomyositis drugs market.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By End-users

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- AstraZeneca group Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis International AG, Pfizer Inc., and Others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

oDeviation from the pre-COVID-19 forecast

oMost affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dermatomyositis Drugs Market Report Segment

By Type

• Abatacept
• Baricitinib
• Dalazatide
• Immune Globulin
• IMP-8400

By end-users

• Hospitals
• Clinics
• Others (Medial Centers, and Pharmacies)

Global Dermatomyositis Drugs Market Report Segment by Region

North America

• The US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea

Rest of Asia-Pacific 

• Rest of the World
• Latin America 
• Middle East & Africa

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/dermatomyositis-drug-market